Akebia stock: buy or sell?
February 18th, 2020
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology.
Should I buy Akebia stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, Akebia stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Akebia stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for AKBA stock for the last 30 days.
Akebia stock analysis
Shares of Akebia Therapeutics boosted an extraordinary 5.03% and closed at $9.19.
Shares of Akebia Therapeutics boosted an extraordinary 5.03% and closed at $9.19. For the last 27 days when SMA100d and SMA200d crossed up, AKBA price gained $1.26 per share (15.89%). Since price and SMA200d lines crossed up on November, AKBA climbed $4.22 (84.91%). AKBA is retaking the upward trend marking a new rising bottom heading to break out over $9.40.
Akebia skyrocketed a brilliant 5.03% this week. Early February AKBA rocketed an exceptional 15.46% in just one week. Late January AKBA plunged a bloodcurdling -9.83% in just one week. This week was the third green week in a row.
Akebia stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since mid January when SMA20w and SMA40w crossed up, AKBA price gained $2.17 per share (30.91%). Since late November 2019 when AKBA stock price broke up the SMA40w line, it gained $4.98 (118.29%).
Akebia stock price history
Akebia IPO was on March 20th, 2014 at $22.90 per share1. Since then, AKBA stock sliced a -59.90%, with a yearly average of -12.00%.
1: Adjusted price after possible price splits or reverse-splits.
Akebia stock historical price chart
AKBA stock reached 52-week highs on Wednesday at $9.40, and all-time highs 2014-06-20 with a price of 31.
Akebia stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last month we have not detected any price forecast for Akebia stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Akebia Therapeutics presented its financial report, posting a dazzling climb for the Earnings per Share (EPS). Experts were expecting $-0.27 per share, but Akebia Therapeutics posted $-0.91.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Akebia annual turnover rocketed a dazzling 14.63% to $207.74 M dollars from $181.23 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) plunged a -28.47% to -69.12%.
|2016||$1.54 M||-||$-135.75 M-8843.5%||-|
|2017||$181 M||11,706.32%||$-73.67 M-40.7%||-45.73%|
|2018||$208 M||14.63%||$-143.59 M-69.1%||94.90%|
Quarterly financial resultsAkebia reported $59.85 million in revenues for 2018-Q4, a 12.57% improvement compared to previous quarter. Reported quarter earnings marked $-60.05 M with a profit margin of -100.34%. Profit margin collapsed a -51.35% compared to previous quarter when profit margin was -48.99%. When comparing revenues to same quarter last year, Akebia Therapeutics sales marked a dreadful drop down and plunged a -31.46%. Looking back to recent quarterly results, Akebia Therapeutics posted 3 negative quarters in a row.
|2017-Q1||$21 M||-||$-44.54 M-213.4%||-|
|2017-Q2||$29 M||36.66%||$-21.52 M-75.5%||-51.68%|
|2017-Q3||$41 M||44.75%||$-23.13 M-56.0%||7.50%|
|2017-Q4||$87 M||111.51%||$12.28 M14.1%||-153.08%|
|2018-Q1||$46 M||-47.40%||$-23.42 M-51.0%||-290.70%|
|2018-Q2||$49 M||6.23%||$-34.07 M-69.8%||45.48%|
|2018-Q3||$53 M||8.97%||$-26.05 M-49.0%||-23.55%|
|2018-Q4||$60 M||12.57%||$-60.05 M-100.3%||130.56%|
Akebia ownershipWhen you are planning to invest in a stock, it's worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Akebia, 3.64% of all outstanding shares are owned by its staff.
In case of Akebia Therapeutics stock, 72.03% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AKBA stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$1.1 B|
|Total shares||118.9 M|
|Float shares||91.4 M|
|- Institutional holdings (%)||72.0%|
|- Insider holdings (%)||3.6%|
|Shares in short selling||0.0%|
|Tuesday, February 18th, 2020|
|Day range||$8.71 - $9.25|
|Average true range||$0.44|
|50d mov avg||$7.30|
|100d mov avg||$5.71|
|200d mov avg||$5.14|
Akebia performanceTo measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Akebia Therapeutics performance to :